| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/07/2004 | EP1434791A2 Specific binding agents of human angiopoietin-2 |
| 07/07/2004 | EP1434788A2 Proteins associated with cell growth, differentiation, and death |
| 07/07/2004 | EP1434786A1 Androstane 17-beta-carboxamides as androgen receptor modulators |
| 07/07/2004 | EP1434785A2 Protein modification and maintenance molecules |
| 07/07/2004 | EP1434782A2 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
| 07/07/2004 | EP1434775A1 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists |
| 07/07/2004 | EP1434773A2 Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| 07/07/2004 | EP1434766A1 Piperidine compounds as muscarinic antagonists |
| 07/07/2004 | EP1434603A2 Method of treatment using ligand-immunogen conjugates |
| 07/07/2004 | EP1434602A2 Cpg formulations and related methods |
| 07/07/2004 | EP1434598A2 Bestrophin and bestrophin homologous proteins involved in the regulation of energy homeostasis |
| 07/07/2004 | EP1434597A1 USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY |
| 07/07/2004 | EP1434588A2 2-(amino-3,4-dioxo-1cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain |
| 07/07/2004 | EP1434587A1 Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma |
| 07/07/2004 | EP1434584A2 Compositions and methods of treatment of cancer |
| 07/07/2004 | EP1434580A2 Allylamides useful in the treatment of alzheimer's disease |
| 07/07/2004 | EP1434579A1 Imidazole derivatives as antiinflammatory agents |
| 07/07/2004 | EP1434573A2 Irrigation solution and method for inhibition of pain and inflammation |
| 07/07/2004 | EP1401431A4 Human growth hormone antagonists |
| 07/07/2004 | EP1212093B1 Use of emu oil as a carrier for antifungal, antibacterial and antiviral medications |
| 07/07/2004 | EP1196195A4 Nasogastric enteral formulations |
| 07/07/2004 | EP1073431B1 Use of nmda antagonists for treatment of irritable bowel syndrome |
| 07/07/2004 | EP1006794A4 A method for treating or preventing alzheimer's disease |
| 07/07/2004 | EP0918519B1 Therapeutic treatment for vegf related occular diseases |
| 07/07/2004 | CN1511157A Novel pyrrole derivatives as pharmaceutical agents |
| 07/07/2004 | CN1511042A PD 4 inhibitor and anti-cholinergic agent in combination for treating obstructive airways diseases |
| 07/07/2004 | CN1511041A Methods of treating antibody-mediated pathologies using agents which inhibit CD 21 |
| 07/07/2004 | CN1511038A Combination therepy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators |
| 07/07/2004 | CN1511037A Nonintestinal estramustine phosphate and albumin preparations |
| 07/07/2004 | CN1511036A Combination comprising signal transduction inhibitor and epothilone derivative |
| 07/07/2004 | CN1511033A Liquid drug preparations |
| 07/07/2004 | CN1511030A Abuse resistant pharmaceutical composition containing capsaicin |
| 07/07/2004 | CN1511017A Treating epidermlyosis bullosa with thymosin Beta-4 |
| 07/07/2004 | CN1509763A Application for human tumour necrosis factor-alpha mutant |
| 07/07/2004 | CN1156583C Parallel ligand index concentration system generating method |
| 07/07/2004 | CN1156274C Medicinal ointment containing zinc conjugated linoleate and sodium humate |
| 07/06/2004 | US6759530 IBD-associated microbial nucleic acid molecules |
| 07/06/2004 | US6759434 Anti-infective compositions, methods and systems for treating disordered tissue |
| 07/06/2004 | US6759432 Prevent denaturing of collagen |
| 07/06/2004 | US6759431 Compositions and methods for treating or preventing diseases of body passageways |
| 07/06/2004 | US6759425 Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
| 07/06/2004 | US6759422 Administering benzothiazole compound for therapy, prophylaxis of disease |
| 07/06/2004 | US6759418 6-(((2s)-2-(alkoxycabonyl)-4,4-difluoropyrrolidinyl)methyl)-1, 2, 3.4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylate, or acid derivatives, useful for treating migraine, and dural protein extravasation |
| 07/06/2004 | US6759413 Use of cox-2 inhibitors as gastroprokinetics |
| 07/06/2004 | US6759399 Using such as gamma-lactone of 10-ethynyl-17-hydroxy-3-oxo-19-nor-17-pregna-4,9(11)-diene-21-carboxylic acid |
| 07/06/2004 | US6759398 Anti-inflammatory androstane derivative |
| 07/06/2004 | US6759396 Compositions based on a synergistic mixture of at least one VDR ligand and a retinoid |
| 07/06/2004 | US6759387 Delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue |
| 07/06/2004 | US6759210 Compositions and methods for the treatment and diagnosis of cardiovascular disease using fehd545 as a target |
| 07/06/2004 | US6759209 For antibiotic drug screening |
| 07/06/2004 | US6759208 Prevention, therapy disease; forming tritiated water; calibration |
| 07/06/2004 | US6759201 Method of identifying a neural progenitor cell by evaluating expression of daedalos |
| 07/06/2004 | US6759194 Nucleotide sequences encoding peroxisome-associated polypeptides, and their uses in the diagnosis and/or treatment of lung injuries and diseases, and of oxidative stress-related disorders |
| 07/06/2004 | US6759062 Composition and method for treating the effects of diseases and maladies |
| 07/06/2004 | US6759058 Enteric-coated proliposomal formulations for poorly water soluble drugs |
| 07/06/2004 | US6759053 Racemic mixtures of n-(prop-2-ynyl)-2-aminophenylpropane, used for the prophylaxis of neurodegenerative disorders and as immunomodulators |
| 07/06/2004 | US6759045 Administering antibodies; anticancer agents |
| 07/06/2004 | CA2303594C Compounds for treating and preventing diabetic complications |
| 07/01/2004 | WO2004055186A1 Guanosine triphosphate-binding protein-coupled receptor |
| 07/01/2004 | WO2004055022A1 Use of cyclolignans as inhibitors of igf-1 receptor for treatment of malignat diseases |
| 07/01/2004 | WO2004054618A1 Drugs for inhibiting rejection reaction in tissue transplanted into mammalian tissue and method of treating diabetes using the same |
| 07/01/2004 | WO2004054588A1 Pharmaceutical compositions comprising a combination of calcitriol and a clobetasol propionate |
| 07/01/2004 | WO2004054582A1 Combination therapy for the treatment of pain |
| 07/01/2004 | WO2004054577A1 Alpha-2-delta ligands to treat ocd and related diseases |
| 07/01/2004 | WO2004054574A1 Solid drug for oral use |
| 07/01/2004 | WO2004054566A1 Pregabalin derivatives for the treatment of fibromyalgia and other disorders |
| 07/01/2004 | WO2004054565A1 Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders |
| 07/01/2004 | WO2004054564A1 Gabapentin analogues for fibromyalgia and other related disorders |
| 07/01/2004 | WO2004054563A1 Alpha-2-delta ligand for the treatment of sexual dysfunction |
| 07/01/2004 | WO2004054562A1 Method for preventing abuse of methylphenidate |
| 07/01/2004 | WO2004054560A1 Alpha-2-delta ligand to treat lower urinary tract symptoms |
| 07/01/2004 | WO2004054559A1 Alpha2delta ligands for different pharmaceutical uses |
| 07/01/2004 | WO2004054554A1 Transdermal buprenorphine to treat pain in sickle cell crisis |
| 07/01/2004 | WO2004054548A1 Method and reagents for treating or preventing atherosclerosis and diseases associated therewith |
| 07/01/2004 | WO2004054538A1 Mastitis treatment |
| 07/01/2004 | WO2004054511A2 Analgesic combination comprising nalbuphine |
| 07/01/2004 | WO2004054510A2 Method for identifying modulators of human orexin-2 receptor |
| 07/01/2004 | WO2004054497A2 Use of a trpm8-activating substance for the treatment of tumours |
| 07/01/2004 | WO2004047673A3 Treatment of liver disease with active vitamin d compounds |
| 07/01/2004 | WO2004037197A3 Antifungal formulations |
| 07/01/2004 | WO2004032979A3 Acidified chlorite compositions containing nitrogenous stabilizers and systems and methods related thereto |
| 07/01/2004 | WO2004030627A3 Synergistic methods and compositions for treating cancer |
| 07/01/2004 | WO2004029025A3 Methods and compositions for the treatment of autoimmune disorders using clofarabine |
| 07/01/2004 | WO2004028446A3 Formulation and method for treating skeletal muscle degeneration caused by malnutrition and disease |
| 07/01/2004 | WO2004023984A3 Novel composition and method for treatment of upper respiratory conditions |
| 07/01/2004 | WO2004020014A3 Method of controlling pharmacokinetics of immunomodulatory compounds |
| 07/01/2004 | WO2004017906A3 Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s) |
| 07/01/2004 | WO2004017894A3 Nutritional supplement for children |
| 07/01/2004 | WO2004010894A3 Ophthalmologic irrigation solutions and method |
| 07/01/2004 | WO2004007747A3 Assays for assembly of ebola virus nucleocapsids |
| 07/01/2004 | WO2004006900A3 Sulphydryl compounds in combination with sulphone or sulphnamide conpounds for use in microbial inflammatory diseases |
| 07/01/2004 | WO2004006865A3 Compounds, compositions, and methods |
| 07/01/2004 | WO2004005323A3 Affinity small molecules for the epo receptor |
| 07/01/2004 | WO2004002420A3 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use |
| 07/01/2004 | WO2003106622A3 Methods for treatment of acute lymphocytic leukemia |
| 07/01/2004 | WO2003106385A3 Process for screening fungitoxic compounds |
| 07/01/2004 | WO2003100435A3 Diagnostics and therapeutic use of neuromedin u receptor 2 (nmu2) |
| 07/01/2004 | WO2003092763A8 Carbon nanotubules for storage of nitric oxide |
| 07/01/2004 | WO2003092716A3 Therapeutic use of pacap, maxadilan, pacap receptor agonist and/or adcyap1r1 in the treatment of cns disorders |
| 07/01/2004 | WO2003092584A3 Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies |